0000893838-19-000020.txt : 20190913 0000893838-19-000020.hdr.sgml : 20190913 20190913163541 ACCESSION NUMBER: 0000893838-19-000020 CONFORMED SUBMISSION TYPE: SC 13G PUBLIC DOCUMENT COUNT: 2 FILED AS OF DATE: 20190913 DATE AS OF CHANGE: 20190913 SUBJECT COMPANY: COMPANY DATA: COMPANY CONFORMED NAME: Cidara Therapeutics, Inc. CENTRAL INDEX KEY: 0001610618 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 461537286 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC 13G SEC ACT: 1934 Act SEC FILE NUMBER: 005-88806 FILM NUMBER: 191092954 BUSINESS ADDRESS: STREET 1: 6310 NANCY RIDGE DRIVE STREET 2: SUITE 101 CITY: SAN DIEGO STATE: CA ZIP: 92121 BUSINESS PHONE: 858-752-6170 MAIL ADDRESS: STREET 1: 6310 NANCY RIDGE DRIVE STREET 2: SUITE 101 CITY: SAN DIEGO STATE: CA ZIP: 92121 FORMER COMPANY: FORMER CONFORMED NAME: K2 THERAPEUTICS, INC. DATE OF NAME CHANGE: 20140611 FILED BY: COMPANY DATA: COMPANY CONFORMED NAME: Mundipharma AG CENTRAL INDEX KEY: 0001787709 IRS NUMBER: 000000000 STATE OF INCORPORATION: V8 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC 13G BUSINESS ADDRESS: STREET 1: ST. ALBAN-RHEINWEG 74 CITY: BASEL STATE: V8 ZIP: 4020 BUSINESS PHONE: 41 61 205 11 11 MAIL ADDRESS: STREET 1: ST. ALBAN-RHEINWEG 74 CITY: BASEL STATE: V8 ZIP: 4020 SC 13G 1 mundipharma13g92019.htm SCHEDULE 13G DATED SEPTEMBER 13, 2019


UNITED STATES
  
SECURITIES AND EXCHANGE COMMISSION
  
Washington, D.C.  20549
  
   
   
 
 
 
SCHEDULE 13G
 
Under the Securities Exchange Act of 1934
 
(Amendment No. __)*
 
CIDARA THERAPEUTICS, INC.
(Name of Issuer)
 
 
Common Stock, $0.0001 par value per share
(Title of Class of Securities)
 
171757107
(CUSIP Number)
 
 
September 3, 2019
(Date of Event Which Requires Filing of this Statement)
 
Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
 
  ☐  Rule 13d–1(b)
  ☒  Rule 13d–1(c)
  ☐  Rule 13d–1(d)
 
*The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.
 
The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).
 
 
 
CUSIP No. 171757107
13G
Page 2 of 5 Pages
 
1
NAMES OF REPORTING PERSONS
 
 
I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)
 
 
 
Mundipharma AG

 
 
 
 
 
2
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
  
(a)☐
  
 
 (b)☐  
 
 
3
SEC USE ONLY
 
 
 
 
 
 
 
4
CITIZENSHIP OR PLACE OF ORGANIZATION
 
 
Switzerland
 
 
 
 
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
5
SOLE VOTING POWER
 
 
4,781,408 shares of Common Stock
 
 
 
 
6
SHARED VOTING POWER
 
 
-0-
 
 
 
 
7
SOLE DISPOSITIVE POWER
 
 
4,781,408 shares of Common Stock
 
 
 
 
8
SHARED DISPOSITIVE POWER
 
 
-0-
 
 
 
 
9
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
 
 
4,781,408 shares of Common Stock
 
 
 
 
10
CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
 
 
☐
 
 
 
 
11
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
 
 
15.2%*
 
 
 
 
12
TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
 
 
CO
 
 
 
 
 
__________

* This calculation is rounded to the nearest tenth and is based upon (i) 26,767,989 shares of Common Stock (as defined below), as disclosed in the Issuer’s (as defined below) Form 10-Q filed with the Securities and Exchange Commission (the “SEC”) on August 8, 2019, plus (ii) 4,781,408 shares of Common Stock issued by the Issuer to the Reporting Person (as defined below) pursuant to that certain Stock Purchase Agreement, dated September 3, 2019, by and between the Issuer and the Reporting Person (the “Stock Purchase Agreement”).
 
 
CUSIP No. 171757107
13G
Page 3 of 5 Pages
 
Item 1(a).
 
Name of Issuer.
 
 
 
 
 
Cidara Therapeutics, Inc. (the “Issuer”)
 
 
 
Item 1(b).
 
Address of Issuer’s Principal Executive Offices.
 
 
 
 
 
The Issuer’s principal executive office address is 6310 Nancy Ridge Dr., Suite 101, San Diego, California 92121.
 
 
 
Item 2(a).
 
Name of Person Filing.
 
 
 
 
 
Mundipharma AG (the “Reporting Person”)
 
 
 
Item 2(b).
 
Address of Principal Business Office or, if None, Residence.
 
 
 
 
 
The Reporting Person’s principal business office address is St. Alban-Rheinweg 74, Basel 4020, Switzerland.
 
 
 
Item 2(c).
 
Citizenship.
 
 
 
 
 
Switzerland
 
 
 
Item 2(d).
 
Title of Class of Securities.
 
 
 
 
 
Common Stock, $0.0001 par value per share (the “Common Stock”)
 
 
 
Item 2(e).
 
CUSIP Number.
 
 
 
 
 
171757107
 Item 3. If This Statement is Filed Pursuant to Rule 13d-1(b), or 13d-2(b) or (c), Check Whether the Person Filing is a:
 (a)
☐
Broker or dealer registered under Section 15 of the Act.
 
(b)
☐
Bank as defined in Section 3(a)(6) of the Act.
 
 (c)
☐
Insurance company as defined in Section 3(a)(19) of the Act.
 
(d)
☐
Investment company registered under Section 8 of the Investment Company Act of 1940.
 
(e)
☐
An investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E).
 
 
 
(f)
☐
An employee benefit plan or endowment fund in accordance with Rule 13d-1(b)(1)(ii)(F).
 
 
 
(g)
☐
A parent holding company or control person in accordance with Rule 13d-1(b)(1)(ii)(G).
 
 
 
(h)
☐
A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act.
 
 
 
(i)
☐
A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act of 1940.
 
 
 
(j)
☐
A non-U.S. institution in accordance with Rule 13d-1(b)(1)(ii)(J).
 
 
 
(k)
☐
Group, in accordance with Rule 13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with Rule 13d-1(b)(1)(ii)(J), please specify the type of institution:__________
 
Not applicable.

 
CUSIP No. 171757107
13G
Page 4 of 5 Pages
 

Item 4. Ownership.
 
(a)
Amount beneficially owned:
 
 
 
4,781,408 shares of Common Stock
 
 
(b)
Percent of class:
 
 
 
15.2%*
 
* This calculation is rounded to the nearest tenth and is based upon (i) 26,767,989 shares of Common Stock, as disclosed in the Issuer’s Form 10-Q filed with the SEC on August 8, 2019, plus (ii) 4,781,408 shares of Common Stock issued by the Issuer to the Reporting Person pursuant to the Stock Purchase Agreement.

(c)
Number of shares as to which the person has:
 
 
 
(i)
Sole power to vote or to direct the vote:
 
 
 
 
 
4,781,408 shares of Common Stock
     
 
(ii)
Shared power to vote or to direct the vote:
 
 
 
 
 
0
 
 
 
 
(iii)
Sole power to dispose or to direct the disposition of:
 
 
 
 
 
4,781,408 shares of Common Stock
 
 
 
 
(iv)
Shared power to dispose or to direct the disposition of:
 
 
 
 
 
0
 
Item 5. Ownership of Five Percent or Less of a Class.
 
If this statement is being filed to report the fact that as of the date hereof the Reporting Persons have ceased to be the beneficial owners of more than five percent of the class of securities, check the following ☐.
 
Item 6. Ownership of More than Five Percent on Behalf of Another Person.
 
Not applicable.
 
Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported by the Parent Holding Company or Control Person.
 
Not applicable.
 
Item 8. Identification and Classification of Members of the Group.
 
Not applicable.
 
Item 9. Notice of Dissolution of Group.
 
Not applicable.

Item 10. Certification.

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.


CUSIP No. 171757107
13G
Page 5 of 5 Pages
 
          After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Dated:  September 13, 2019

MUNDIPHARMA AG
 
 
 By: /s/ Frank Vellucci    

 Name: Frank Vellucci
Title:    Attorney-in-Fact
        

     
Attention. Intentional misstatements or omissions of fact constitute federal criminal violations (see 18 U.S.C. 1001).
 
 
 
EXHIBIT INDEX
 
     
Exhibit
 
Description of Exhibit
   
99.1
 
Power of Attorney, dated as of September 6, 2019, granted by Mundipharma AG in favor of Bryan Lea, Neil Jasani and Frank Vellucci.
     




EX-99.1 2 powerofattorney.htm POWER OF ATTORNEY

Exhibit 99.1

Power of Attorney

The undersigned, as a Section 13(d) reporting person and potential Section 16 reporting person of Cidara Therapeutics, Inc. (the “Company”) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), hereby constitutes and appoints each of Bryan Lea, Neil Jasani and Frank Vellucci, acting individually with full power of substitution, as the undersigned’s true and lawful attorney-in-fact to:
1.
Complete and execute Forms 3, 4, 5, and 144, Schedules 13D and 13G and Form ID (Uniform Application for Access Codes to File on EDGAR) and other forms and all amendments thereto as such attorney-in-fact shall in his discretion determine to be required or advisable pursuant to Section 16(a) and Section 13(d) of the Exchange Act, and the rules and regulations promulgated thereunder, or any successor laws and regulations, as a consequence of the undersigned’s ownership, acquisition or disposition of securities of the Company;
2.
Do and perform any and all acts for and on the behalf of the undersigned which may be necessary or desirable in order to complete and execute any such form, complete and execute any amendments thereto, and timely file such forms with the Securities and Exchange Commission, any securities exchange or national association, the Company and such other person or agency as the attorney-in-fact shall deem appropriate; and
3.
Take any other action of any type whatsoever in connection with the foregoing which, in the opinion of such attorney-in-fact, may be of benefit to, in the best interest of, or legally required by, the undersigned, it being understood that the documents executed by such attorney-in-fact on behalf of the undersigned pursuant to this Power of Attorney shall be in such form and shall contain such terms and conditions as such attorney-in fact may approve in such attorney-in-fact’s discretion.
The undersigned hereby grants to each attorney-in-fact full power and authority to do and perform any and every act and thing whatsoever requisite, necessary, or proper to be done in the exercise of any of the rights and powers herein granted, as fully to all intents and purposes as the undersigned might or could do if personally present, with full power of substitution or revocation, hereby ratifying and confirming all that each attorney-in-fact, or each attorney-in-fact’s substitute or substitutes, shall lawfully do or cause to be done by virtue of this Power of Attorney and the rights and powers herein granted. The undersigned acknowledges that each attorney-in-fact, in serving in such capacity at the request of the undersigned, is not assuming any of the undersigned’s responsibilities to comply with Sections 16 and 13(d) of the Exchange Act.

This Power of Attorney shall remain in full force and effect until the undersigned is no longer required to file Forms 3, 4, 5 or 144 or Schedules 13D or 13G with respect to the undersigned’s holdings of and transactions in securities issued by the Company, unless earlier revoked by the undersigned in a signed writing delivered to each attorney-in-fact.

[Remainder of Page Intentionally Left Blank]

IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be executed as of September 6, 2019.

   
MUNDIPHARMA AG
 
 
/s/ Sonja Nagy
   
By: Sonja Nagy
Title: Deputy Director
     
   
/s/ Fabian Kaslin
   
By: Fabian Kaslin
Title: Authorized Signatory